EC Number   |
Reference |
|---|
   3.4.21.21 | - |
717489 |
| 3.4.21.21 | 2 A resolution crystal structure of a zymogen form of factor VII comprising the EGF2 and protease domains is revealed in a complex with the exosite binding inhibitory peptide A-183 and a vacant active site, hanging-drop method |
657378 |
| 3.4.21.21 | crystal structure at 2.0 A resolution of active-site-inhibited factor VIIa complexed with the cleaved extracellular domain of tissue factor |
95333 |
| 3.4.21.21 | crystal structure of factor FVIIa is inhibited at the active site with 1,5-dansyl-Glu-Gly-Arg-chloromethyl ketone and lacking the Gla domain |
95330 |
| 3.4.21.21 | enzyme complexed with acetyl-ALCDDPRVDRWYCQFVEG-NH2, hanging-drop method |
656859 |
| 3.4.21.21 | hanging drop vapor diffusion method, using 0.1 M sodium citrate buffer at pH 5.1, 16.6% PEG 3350, 12.5% (v/v) 1-propanol, or 0.1 M cacodylate buffer at pH 5.6, 12% (w/v) PEG 8000 |
754141 |
| 3.4.21.21 | hanging drop vapour diffusion method |
669430 |
| 3.4.21.21 | in complex with tissue factor |
754202 |
| 3.4.21.21 | N-terminally truncated factor VII, activated recombinant factor VII is crystallized in the presence of the reversible S1-site inhibitor benzamidine |
656505 |
| 3.4.21.21 | purified complex between Trp-Tyr-Thr-Arg-cmk-FVIIa and sTF1?209, hanging drop vapour diffusion method, 10 mg/ml protein in 10 mM Tris-HCl, pH 7.5, 100 mM NaCl and 2 mM CaCl2, with 0.1 M sodium citrate, 16.515.5% w/v PEG 4000 and 12% v/v propan-1-ol, pH 5.6, as the precipitating agent, X-ray diffraction structure determination and analysis, modeling |
683139 |
